Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2018 1
2019 1
2020 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Cannabis and cannabinoids.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-182. Med Lett Drugs Ther. 2019. PMID: 31770357 Review. No abstract available.
Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA).
Lorusso V, Russo A, Giotta F, Codega P. Lorusso V, et al. Core Evid. 2020 Jul 27;15:21-29. doi: 10.2147/CE.S203634. eCollection 2020. Core Evid. 2020. PMID: 32802009 Free PMC article. Review.
In fact, this combination is actually widely used and recommended for CINV prophylaxis for highly emetogenic cisplatin-based adriamycin/cyclophosphamide (AC) and carboplatin-based regimens. NEPA (netupitant/palonosetron) is the only fixed combination antiemetic available a …
In fact, this combination is actually widely used and recommended for CINV prophylaxis for highly emetogenic cisplatin-based adriamycin/cycl …
Comparison of the ED50 of prophylactic butorphanol in preventing morphine-induced pruritus with or without palonosetron: a prospective, double-blinded, randomized dose-response trial using an up-down sequential allocation method.
Sun L, Jin L, Jiao C, Wang L, Xu Q, Wu H, Chen X. Sun L, et al. Ann Med. 2023;55(2):2304671. doi: 10.1080/07853890.2024.2304671. Epub 2024 Jan 17. Ann Med. 2023. PMID: 38233748 Free PMC article. Clinical Trial.
BACKGROUND: Butorphanol has been used to reduce the incidence and severity of neuraxial morphine-induced pruritus. Palonosetron is a commonly used antiemetic for the prevention of postoperative nausea and vomiting. The aim of our study was to compare the effective dose in …
BACKGROUND: Butorphanol has been used to reduce the incidence and severity of neuraxial morphine-induced pruritus. Palonosetron is a …
Effect of intravenous palonosetron on hypotension induced by spinal anesthesia for cesarean section: A randomized controlled trial.
Kim MK, Kim I, Kang H, Wi W, Park YH, Jung YH, Woo YC, Baek CW. Kim MK, et al. PLoS One. 2024 Jun 25;19(6):e0305913. doi: 10.1371/journal.pone.0305913. eCollection 2024. PLoS One. 2024. PMID: 38917195 Free PMC article. Clinical Trial.
METHODS: Fifty-four women scheduled for elective cesarean section were, randomly allocated to ondansetron group (n = 27) or palonosetron group (n = 27). Ten minutes prior to the administration of spinal anesthesia, participants received an intravenous injection of either o …
METHODS: Fifty-four women scheduled for elective cesarean section were, randomly allocated to ondansetron group (n = 27) or palonosetron
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
Minatogawa H, Izawa N, Kawaguchi T, Miyaji T, Shimomura K, Kazunori H, Iihara H, Ohno Y, Inada Y, Arioka H, Morita H, Hida N, Sugawara M, Katada C, Nawata S, Ishida H, Tsuboya A, Tsuda T, Yamaguchi T, Nakajima TE. Minatogawa H, et al. BMJ Open. 2020 Dec 17;10(12):e041737. doi: 10.1136/bmjopen-2020-041737. BMJ Open. 2020. PMID: 33334838 Free PMC article. Clinical Trial.
Although our multicentre randomised double-blind comparative study verified non-inferiority of sparing DEX after day 2 of chemotherapy when combined with neurokinin-1 receptor antagonist (NK1-RA) and palonosetron (Palo) for patients receiving HEC regimen, DEX sparing was n …
Although our multicentre randomised double-blind comparative study verified non-inferiority of sparing DEX after day 2 of chemotherapy when …
Effect of low-dose esketamine on pain control and postpartum depression after cesarean section: a retrospective cohort study.
Wang Y, Zhang Q, Dai X, Xiao G, Luo H. Wang Y, et al. Ann Palliat Med. 2022 Jan;11(1):45-57. doi: 10.21037/apm-21-3343. Ann Palliat Med. 2022. PMID: 35144397 Free article.
Parturients in the control group received 50 g sufentanil citrate and 0.25 mg palonosetron hydrochloride, while those in the experimental group received additional 0.2-0.5 mg/kg esketamine. ...
Parturients in the control group received 50 g sufentanil citrate and 0.25 mg palonosetron hydrochloride, while those in the experime …
Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer.
Fleishman SB, Mahajan D, Rosenwald V, Nugent AV, Mirzoyev T. Fleishman SB, et al. J Oncol Pract. 2012 May;8(3):136-40. doi: 10.1200/JOP.2010.000151. Epub 2011 Dec 20. J Oncol Pract. 2012. PMID: 22942805 Free PMC article.
Seven patients (11%) had a history of motion sickness; 13 of 28 women (46%) reported history of pregnancy-induced morning sickness. Palonosetron slightly but significantly reduced the occurrence of nausea. ...
Seven patients (11%) had a history of motion sickness; 13 of 28 women (46%) reported history of pregnancy-induced morning sickness. …